Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis

MICHAEL W. CLIMO, 1, 2 ROBERTO L. PATRON, 1 BETH P. GOLDSTEIN, 2 AND GORDON L. ARCHER 1, 3

Department of Internal Medicine 1 and Microbiology/Immunology, 3 Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia, and AMBI, Inc., Tarrytown, New York 2

Received 2 January 1998/Returned for modification 5 March 1998/Accepted 25 March 1998

The emergence of clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted a search for new and novel therapeutic agents active against S. aureus. Lysostaphin, a peptidase produced by Staphylococcus simulans, specifically cleaves the glycine-glycine bonds unique to the interpeptide cross-bridge of the S. aureus cell wall. The effectiveness of various regimens of dosing with intravenous lysostaphin was compared to that of vancomycin in the rabbit model of aortic valve endocarditis caused by a clinical methicillin-resistant S. aureus isolate. All animals were treated for a total of 3 days. The most active regimen, lysostaphin given three times daily, produced sterile vegetations in 10 of 11 treated rabbits, with a mean reduction in vegetation bacterial counts of 8.5 log10 CFU/g compared to the counts in the untreated controls. In contrast, vancomycin given twice daily sterilized no vegetations and reduced vegetation bacterial counts by only 4.8 log10 CFU/g. Lysostaphin given once daily was less effective, reducing mean vegetation bacterial counts by only 3.6 log10 CFU/g, but the combination of lysostaphin once daily and vancomycin twice daily reduced the mean vegetation bacterial density by 7.5 log10 CFU/g, a result that was significantly better than that for either regimen alone (P < 0.05). Lysostaphin was well tolerated by the rabbits, with no evidence of immunological reactions following up to 9 weeks of intravenous administration. We conclude that lysostaphin given alone or in combination with vancomycin is more effective in the treatment of experimental methicillin-resistant S. aureus aortic valve endocarditis than vancomycin alone.

Vancomycin is the treatment of choice for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, despite the susceptibility in vitro of most clinical isolates of MRSA to vancomycin, failure of vancomycin therapy has been reported in 14 to 35% of patients with endocarditis caused by this organism (29, 42). The high vancomycin failure rate and the lack of alternative therapeutic agents has prompted a search for newer antimicrobial agents with activity against MRSA. The emergence of vancomycin-resistant strains of enterococci (12) and the recent discovery of strains of MRSA with decreased susceptibility to vancomycin (2, 4, 25, 38, 43) emphasize this need.

Lysostaphin is a 27-kDa peptidase produced by Staphylococcus simulans and was isolated in 1960 by Schindler and Schuhardt, as described previously (39, 41, 45). Lysostaphin specifically cleaves the pentaglycine cross-links unique to the cell wall of S. aureus and lysases in all metabolic states (growing, resting, or heat killed). Because staphyloccoci are highly resistant to lysis with such standard agents as lysozyme or detergents, lysostaphin has been widely used in research laboratories as a staphylohytic agent. Lysostaphin was studied in the 1960s and 1970s as a potential therapeutic agent in numerous animal models and in a single human patient (3, 15, 21, 23, 24, 33, 40, 44, 45). However, although its antimicrobial properties appeared promising, development of lysostaphin as a therapeutic agent was abandoned. Some of the reasons for failure to pursue the clinical use of lysostaphin included the availability of antistaphylococcal antibiotics, fears concerning the potential immunogenicity of a parenterally administered protein, and the impurity of lysostaphin preparations. The availability of recombinant lysostaphin that is ≥90% pure and that can be produced in quantity from Bacillus sphaericus (37) has provided an opportunity to assess the efficacy of lysostaphin in an animal model of S. aureus endocarditis and to compare it to the efficacy of standard therapy with vancomycin. We assessed the susceptibility of MRSA to lysostaphin in vitro, determined its therapeutic efficacy in the rabbit model of aortic valve MRSA endocarditis, and evaluated its toxicity and immunogenicity after long-term administration.

MATERIALS AND METHODS

Bacterial strains. S. aureus 27619, a homotypically methicillin-resistant isolate, was used to challenge rabbits. Additional MRSA strains were taken from a collection of clinical strains maintained at the Medical College of Virginia as described previously (13). Two S. aureus isolates with reduced susceptibility to vancomycin were kindly provided by Fred Tenover, Centers for Disease Control and Prevention (4, 38, 43). A final S. aureus strain with reduced susceptibility to vancomycin was an isogenic derivative of S. aureus 27619, designated 27619VR, which was produced through stepwise passage in the presence of increasing concentrations of glycopeptides. MICs were determined by a broth microdilution method in cation-adjusted Mueller-Hinton broth (Becton Dickinson, Cockeysville, Md.) according to standards of the National Committee for Clinical Laboratory Standards with a final inoculum of 104 CFU/ml (31). The MICs of lysostaphin were determined following the addition of 0.1% bovine serum albumin (Sigma). Bovine serum albumin prevents the absorption of lysostaphin to polystyrene microtiter wells. The lowest concentration of antibiotic yielding no visible growth after incubation at 37°C for 24 h was taken as the MIC.

Experimental infection. The rabbit model of aortic valve endocarditis, as described previously (35), was used to evaluate antibiotic treatment regimens. Seventy-two hours after transcarotid placement of a polyethylene catheter across the aortic valve, rabbits were injected intravenously through the marginal ear vein with 1 ml of an overnight culture containing 107 CFU of MRSA strain 27619 per ml. Blood samples for culture were obtained 24 h later, and the rabbits were randomly assigned to one of the following treatment groups: lysostaphin at 5 mg/kg of body weight given intravenously (i.v.) every 8 h (t.i.d.), lysostaphin at 5 mg/kg given i.v. once a day (q.d.), vancomycin at 30 mg/kg given i.v. every 12 h (b.i.d.), lysostaphin at 5 mg/kg given i.v. q.d. plus vancomycin at 30 mg/kg given i.v. b.i.d., or no treatment (control group). The surviving animals were killed by i.v. administration of pentobarbital after a total of 3 days of antibiotic treatment.
Lysostaphin was serially diluted in microtiter wells in a volume of 50 μl of serum from immunized rabbits was added. Finally, 25 μl of the test organism, S. aureus 27619, was added at a concentration that resulted in a final inoculum of 10^3 CFU/ml. Pooled commercial rabbit serum served as a negative control. The MIC was that concentration of lysostaphin yielding no visible growth after 24 h of incubation at 37°C.

**RESULTS**

**In vitro studies.** The MICs of antibacterial agents for S. aureus 27619, the isolate used in the rabbit endocarditis model, were as follows: oxacillin, >100 μg/ml; vancomycin, 1 μg/ml; and lysostaphin, 0.03 μg/ml. For 16 additional MRSA strains, the MICs of lysostaphin ranged from 0.007 to 0.125 μg/ml. Lysostaphin demonstrated similar activity (MICs, 0.015 to 0.030 μg/ml) against three MRSA isolates with reduced susceptibility (MIC, 8 μg/ml) to vancomycin.

**Serum bactericidal activity and long-term tolerability.** Lysostaphin exhibited excellent serum bactericidal activity in rabbits. To assess the long-term tolerability and activity of lysostaphin, uninfected rabbits received weekly i.v. injections of lysostaphin (15 mg/kg) for a total of 9 weeks. At 9 weeks, rabbits demonstrated serum bactericidal levels of 1:128 4 h following i.v. dosing. In addition, measurable bactericidal activity was still present 12 h postdosing.

Although rabbits still demonstrated high levels of lysostaphin in serum following 9 weeks of treatment, as evidenced by serum bactericidal activity, there was evidence of neutralizing antibody formation. Serum obtained from treated rabbits did appear to inhibit the lytic activity of lysostaphin in broth microdilution MIC determinations. The addition of serum from rabbits treated with lysostaphin for 9 weeks raised the MICs at least eightfold compared to the MICs determined in the presence of nonimmune rabbit serum.

Lysostaphin was well tolerated by the rabbits during long-term dosing. There was no evidence of hypersensitivity reactions during the 9-week dosing period. Rabbits did not develop proteinuria. Finally, both rabbits underwent autopsy and pathological examination of the kidneys at the end of the 9-week dosing trial. The kidneys from the first rabbit were normal, and the other rabbit demonstrated nonspecific plasma cellular interstitial nephritis on examination.

**Bacterial clearance in the rabbit model of endocarditis.** The results of the bacterial clearance studies are presented in Fig. 1. In the treatment of endocarditis, both lysostaphin and vancomycin had similar effects on bacterial clearance. Following the administration of a single dose of vancomycin (60 mg/kg) or lysostaphin (15 mg/kg) to rabbits with experimental endocarditis, there were similar rates of bacterial clearance for both agents. Twelve hours after the administration of a single dose, blood from all three rabbits treated with vancomycin and two of three rabbits treated with lysostaphin were sterile on culture. All rabbits had a return to positive blood cultures by 30 h postdosing.
Endocarditis. The results obtained from the 3-day antibiotic treatment regimen used to treat experimental endocarditis caused by MRSA 27619 are presented in Table 1. A total of 56 rabbits infected with MRSA 27619 were assigned to the various treatment regimens. Control rabbits had a mean aortic valve vegetation bacterial count of 10.79 ± 1.58 (standard deviation [SD]) log_{10} CFU/g, which is comparable to those reported previously from trials of MRSA endocarditis (1, 5, 6, 9, 10, 13, 14, 34).

All treatment regimens reduced aortic valve vegetation bacterial counts significantly (P < 0.05) compared with the counts in the vegetations from the controls. The most effective treatment arm was lysostaphin at 5 mg/kg given i.v. t.i.d., with a mean aortic valve vegetation bacterial count of 2.26 ± 0.85 (SD) log_{10} CFU/g. That is a mean reduction of 8.5 log_{10} CFU/g compared with the counts in the controls (P < 0.05). The second most effective treatment arm was the combination of lysostaphin at 5 mg/kg given i.v. q.d. with vancomycin at 30 mg/kg given i.v. b.i.d., with a mean aortic valve vegetation bacterial count of 3.23 ± 1.41 (SD) log_{10} CFU/g, which was a mean reduction of 7.5 log_{10} CFU/g compared with the counts in the controls (P < 0.05). The combination of lysostaphin at 5 mg/kg given i.v. q.d. with vancomycin at 30 mg/kg given i.v. b.i.d. was significantly better than either regimen alone (vancomycin b.i.d. or lysostaphin q.d.) at reducing mean aortic valve bacterial counts (P < 0.05). Lysostaphin at 5 mg/kg given i.v. q.d. also achieved a statistically significant (P < 0.05) reduction in the mean aortic valve vegetation bacterial counts compared with the counts in the controls (mean reduction: 3.6 log_{10} CFU/g). Rabbids treated with lysostaphin at 5 mg/kg given i.v. t.i.d. had significantly lower mean bacterial titers than those treated with vancomycin b.i.d. Mean aortic valve vegetation bacterial counts were 3.48 log_{10} CFU/g lower in the group given lysostaphin t.i.d. than in the vancomycin treatment group (2.26 versus 5.74 log_{10} CFU/g; P < 0.05). Although mean bacterial counts were lower for rabbits treated with lysostaphin t.i.d. (2.26 log_{10} CFU/g) than the combination of lysostaphin q.d. with vancomycin b.i.d. (3.23 log_{10} CFU/g), these differences were not statistically significant.

Rates of sterilization of aortic valve vegetation were significantly better in rabbits treated with regimens containing lysostaphin. All three lysostaphin regimens produced sterile aortic valve vegetation cultures, while no sterile aortic valve vegetation cultures were seen for rabbits treated with vancomycin alone. Lysostaphin at 5 mg/kg given i.v. t.i.d. sterilized the cultures of aortic valve vegetations from 91% (10 of 11) of the treated rabbits after 3 days of treatment. Although lysostaphin at 5 mg/kg given i.v. t.i.d. was not significantly better than the combination of lysostaphin with vancomycin in reducing mean aortic valve vegetation bacterial counts, the rate of sterilization (10 of 11 [91%] versus 3 of 11 [27%]) was significantly better (P = 0.019).

Table 1 depicts the results of kidney tissue cultures for the different treatment groups. Similar rates of kidney tissue abscess sterilization were seen with vancomycin (67%), lysostaphin at 5 mg/kg given i.v. t.i.d. (72%), and the combination of lysostaphin q.d. with vancomycin b.i.d. (70%). All treatment regimens reduced mean bacterial counts in the kidneys compared with the counts in the kidneys of the controls (P < 0.05), and no statistically significant difference was observed among the treated groups.

**DISCUSSION**

The treatment of serious infections caused by MRSA requires prolonged i.v. administration of bactericidal antibiotics. Since these strains are resistant to all β-lactams, glycopeptides such as vancomycin or teicoplanin are considered the treatments of choice. Despite the universal susceptibility of *S. aureus* to vancomycin, clinical failures in patients with severe MRSA infections are not uncommon (29, 42). Relapse rates of up to 15% have been reported following the treatment of endocarditis due to *S. aureus* with vancomycin (42). Many investigators have also suggested that the duration of *S. aureus* bacteremia is prolonged with vancomycin treatment compared to that with β-lactam treatment (29). Although the effectiveness of vancomycin in animal models of endocarditis can be improved with the addition of aminoglycosides and rifampin (1, 34), studies demonstrating effective alternative therapeutic agents in the treatment of MRSA endocarditis have been lacking.

In the studies reported above, we investigated the efficacy of lysostaphin compared to that of vancomycin in the treatment of experimental endocarditis due to MRSA. Lysostaphin given t.i.d. was significantly more effective than vancomycin at reducing the mean vegetation bacterial counts, producing sterile vegetations in 91% of rabbits, while vancomycin sterilized the vegetations in none of the rabbits. Our experiments did not examine rabbits for evidence of relapse, although the high rate of sterilization would argue against a risk for relapse among rabbits treated with lysostaphin t.i.d. However, in rabbits treated with vancomycin or lower doses of lysostaphin, in which vegetation bacterial counts were higher, there may be a significantly higher risk of relapse. Lysostaphin was also an effective adjunctive treatment when it was given in combination with vancomycin. The addition of lysostaphin q.d. to vancomycin reduced the mean aortic valve vegetation counts by 2.5 log_{10} CFU/g compared to those after treatment with vancomycin alone (3.23 versus 5.91 log_{10} CFU/g).

The reductions in aortic valve vegetation counts and rates of sterilization...
sterilization seen with lysostaphin in our study are the highest reported for single agents in the rabbit model of MRSA endocarditis (Table 2). The most effective single-agent regimens used to treat experimental MRSA endocarditis in the rabbit have been glycopeptides, either teicoplanin or vancomycin, with aortic valve sterilization rates of 27 to 80% reported for teicoplanin and sterilization rates of 0 to 87% reported for vancomycin. Although vancomycin is considered the best agent in this model, it is relatively ineffective at sterilizing aortic valve vegetations, results that mirror the lack of efficacy reported for vancomycin therapy of human S. aureus endocarditis. Of 15 studies of experimental MRSA aortic valve endocarditis with vancomycin doses and treatment durations similar to those used in our study, 6 reported no sterilization of aortic valve vegetations (5, 7, 13, 16, 18, 19), while 4 described sterilization of fewer than half of the vegetations (1, 6, 10, 32). Five remaining studies (11, 14, 26–28) reported aortic valve sterilization rates of 55 to 87%, although three of those studies used an MRSA strain that appears to have been more easily eradicated by a variety of antimicrobial agents in this model (26–28). Overall, 67% of studies with vancomycin for the treatment of experimental endocarditis due to MRSA have reported sterilization of aortic valve vegetations for fewer than half of treated animals.

Lysostaphin was first tested in animal models of staphylococcal infection in the 1960s (15, 21, 23, 24, 40, 41). Most of that work was with mice, and acute intraperitoneal infection or renal abscess models and standard penicillin-susceptible S. aureus strains were used. Lysostaphin was clearly efficacious in those models. Although the doses were as high as 100 mg/kg, the purity or potency of the lysostaphin preparations used was not always reported, so the true doses of the active ingredient may have been significantly lower in some cases. In one study (24), a very rapid reduction in kidney bacterial loads was demonstrated with single lysostaphin doses as low as 1.5 or 3 mg/kg; among the other agents tested, only penicillin G benzathine (Bicillin; at 25 or 100 mg/kg) gave results comparable to those achieved with lysostaphin. There is also a report of therapy of endocarditis in dogs caused by a penicillinase-producing S. aureus strain (21). That study was of an exploratory nature, and only one or a few dogs with documented endocarditis were treated with any given regimen of lysostaphin. Some evidence of efficacy was seen with dosages of 50 mg/kg/treatment or greater.

In humans, a lysostaphin spray was shown to eradicate S. aureus from the nares of 80% of carriers (30). One human patient has been treated with a single 500-mg i.v. dose of lysostaphin (44). The patient was suffering from acute myelocytic leukemia with profound pancytopenia and severe daunorubicin-induced cardiomyopathy. During his period of pancytopenia, he developed MRSA pneumonia and abscesses of the buttocks, thighs, and arms. He failed to respond to 3 weeks of treatment with antistaphylococcal antibiotics including nafcillin, methicillin, vancomycin, and cephalothin. Prior to the i.v. dosing, the patient demonstrated a 5-mm erythematous reaction to the intracutaneous administration of lysostaphin. A brief episode of flushing, hypotension, and tachycardia was noted following i.v. dosing, but the episode resolved with diphenhydramine and epiptephrine. Unfortunately, the patient died of progressive heart failure 3 days after the lysostaphin infusion. Prior to death and at autopsy there was no evidence of staphylococcal infection, with negative cultures of samples of blood, lungs, and abscess sites. There was no examination for the presence of antibody directed against lysostaphin. The investigators concluded that further trials of lysostaphin treatment as adjunctive treatment for severe staphylococcal infections were warranted.

Since those studies were reported, rabbit and rat models of MRSA endocarditis have been established and are widely used to assess new therapeutic regimens. Our studies with the rabbit indicate that lysostaphin may be an effective therapeutic agent for the treatment of serious staphylococcal infections, despite concerns about potential immunogenicity. Lysostaphin was well tolerated by the rabbits, even with prolonged treatment for up to 9 weeks. In particular, there was no evidence of serum sickness, as assessed by the absence of fever, weight loss, pro-

<table>
<thead>
<tr>
<th>Antimicrobial agent</th>
<th>Mean reductions in aortic valve vegetations (log_{10} CFU/g)</th>
<th>Sterilization rates (%)</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td>1–6.96</td>
<td>0–87</td>
<td>5–7, 9–11, 13, 14, 16, 18, 26, 28, 32</td>
</tr>
<tr>
<td>Teicoplanin</td>
<td>4.2–6.06</td>
<td>11–80</td>
<td>8, 10, 14, 28</td>
</tr>
<tr>
<td>Ampicillin-sulbactam</td>
<td>0–4.8</td>
<td>0–31</td>
<td>7, 11</td>
</tr>
<tr>
<td>Cephalothin</td>
<td>1.1</td>
<td>0</td>
<td>6, 9</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>5.08</td>
<td>52</td>
<td>26</td>
</tr>
<tr>
<td>Enoxacin</td>
<td>4.2</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Fleroxacin</td>
<td>6.1</td>
<td>67</td>
<td>27</td>
</tr>
<tr>
<td>FK037</td>
<td>3.3–6.24</td>
<td>9–37</td>
<td>13</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td>1.1</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>3.6</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Imipenem</td>
<td>1–4.9</td>
<td>0–33</td>
<td>5, 11, 13</td>
</tr>
<tr>
<td>L-695,256 (carbapenem)</td>
<td>3.7</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Minocycline</td>
<td>3.4</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>Nafcillin</td>
<td>2.9</td>
<td>14</td>
<td>11</td>
</tr>
<tr>
<td>Penicillin</td>
<td>0–4.73</td>
<td>0–25</td>
<td>5, 19</td>
</tr>
<tr>
<td>Rifampin</td>
<td>0–2.45</td>
<td>0–10</td>
<td>1.7</td>
</tr>
<tr>
<td>RP 59500</td>
<td>1.5–3.1</td>
<td>0</td>
<td>17, 18</td>
</tr>
<tr>
<td>Ticarceillin-clavulanate</td>
<td>1.5</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole</td>
<td>0.83</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Lysostaphin</td>
<td>8.47</td>
<td>91</td>
<td>Present study</td>
</tr>
</tbody>
</table>

* Treatment regimens were completed over 3 to 4 days with the rabbit model of experimental aortic valve endocarditis.
* Mean reductions in counts (log_{10} CFU per gram of vegetation) compared to the counts for untreated control animals.
* Rates of sterilization of aortic valve vegetation material.
teiniuria, joint swelling, or histologic renal lesions, following prolonged dosing. Rabbits demonstrated evidence of the presence of neutralizing antibodies following extended dosing, as indicated by an eightfold reduction of the lytic action of lysostaphin in the presence of immune serum. Despite the presence of neutralizing antibodies, high levels of serum bactericidal activity persisted. This is in concordance with earlier studies with the rabbit, in which Schaeffner et al. (40) demonstrated the presence of neutralizing and precipitating antibodies in the rabbit following repeated i.v. dosing. However, as in our own study, no adverse reactions were seen by those investigators following the administration of multiple doses.

Data on the immunogenicity of lysostaphin in human subjects is largely limited to studies evaluating its topical use. Among patients treated with topical lysostaphin in attempts to eradicate nasal staphylococcal carriage, there has been little evidence of sensitization or induced antibody formation (22, 36). Protein products such as thrombolytic enzymes (streptokinase) have been used with success for some time to treat humans with a low rate of medically manageable hypersensitivity reactions. These observations, in conjunction with previous data from studies with animals, would indicate that short-term or adjunctive therapy with lysostaphin may be possible in humans. These studies also highlight the potential for the use of peptides as antimicrobial agents. Although lysostaphin is a large protein of approximately 27 kDa, its effectiveness in the treatment of experimental endocarditis caused by multi- ormeticillin-resistant Staphylococcus aureus endocarditis in rabbits. Agents Chemother. 26:61–64.


2. Chambers, H. F., and M. A. Sande. 1984. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by multi-


